Lineage Cell Therapeutics, Inc. (LCTX)

NYSEAMERICAN: LCTX · Real-Time Price · USD

1.030

0.00 (0.00%)

At close: Sep 18, 2026, 4:00 PM EDT

1.040

+0.010 (0.97%)

After-hours: Sep 18, 2026, 8:00 PM EDT

Market Cap	260.49M -17.9%
Revenue (ttm)	13.08M +19.9%
Net Income	-32.26M
EPS	-0.19
Shares Out	252.91M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,209,250
Open	1.020
Previous Close	1.030
Day's Range	1.000 - 1.055
52-Week Range	1.000 - 2.090
Beta	1.55
Analysts	Strong Buy
Price Target	5.50 (+433.98%)
Earnings Date	Nov 5, 2026

About LCTX

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It a... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1990

Employees 77

Stock Exchange NYSEAMERICAN

Ticker Symbol LCTX

Website https://www.lineagecell.com

Full Company Profile

Financial Performance

In 2025, Lineage Cell Therapeutics's revenue was $14.56 million, an increase of 53.24% compared to the previous year's $9.50 million. Losses were -$63.53 million, 241.4% more than in 2024.

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for LCTX stock is "Strong Buy." The 12-month stock price target is $5.5, which is an increase of 433.98% from the latest price.

Price Target

$5.5

(433.98% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

Lineage Cell announces issuance of patent underlying AlloSCOPE 5D platform

Lineage Cell Therapeutics (LCTX) announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,692,476, with claims covering the Company’s proprietary AlloSCOPE ce...

12 days ago - TheFly

Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--AlloSCOPE 5D Patent Release.

12 days ago - Business Wire

Lineage Cell Therapeutics management to meet with B. Riley

Meeting to be held on August 25 in San Francisco and in Los Angeles on August 26 hosted by R. Riley.

27 days ago - TheFly

Lineage Cell Therapeutics Earnings Call Transcript: Q2 2026

Q2 2026 saw continued pipeline progress, with OpRegen advancing under Roche, rapid development in COR1 and ILT1, and a shift to chronic SCI patients for OPC1. Cash runway extends into Q3 2028, with net income of $1.5 million driven by non-cash gains and disciplined expense management.

6 weeks ago - Transcripts

Lineage Cell Therapeutics Earnings release: Q2 2026

Lineage Cell Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.

6 weeks ago - Filings

Lineage Cell Therapeutics Quarterly report: Q2 2026

Lineage Cell Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.

6 weeks ago - Filings

Lineage Cell Therapeutics reports Q2 EPS (3c), consensus (3c)

Reports Q2 revenue $1.069M, consensus $1.53M. “As we continue to support our collaboration with Roche and Genentech for their clinical development of OpRegen, Lineage remains focused on building out o...

6 weeks ago - TheFly

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Q2 2026 Earnings Release.

6 weeks ago - Business Wire

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogenei...

7 weeks ago - Business Wire

Lineage Cell Therapeutics Transcript: Study update

COR1, an allogeneic cell therapy for corneal endothelial disease, leverages a proprietary scalable manufacturing platform to address the global shortage of donor corneas. The program emphasizes robust process development, high product quality, and cost-effective, minimally invasive delivery, with preclinical animal data expected this year.

2 months ago - Transcripts

Lineage Cell Therapeutics Press release: Study update

Lineage Cell Therapeutics issued a press release on July 13, 2026, disclosing material business information to investors.

2 months ago - Filings

Lineage Cell Therapeutics provides update on COR1 program

Lineage Cell provided an update on COR1, the Company’s allogeneic corneal endothelial cell transplant program, in preclinical development for the treatment of corneal endothelial disease. With COR1, L...

2 months ago - TheFly

Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease

2 months ago - Business Wire

Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

2 months ago - Business Wire

Lineage Cell Therapeutics reports Q1 EPS (3c), consensus (2c)

Reports Q1 revenue $1.73M, consensus $3.6M. “This quarter, we continued to build on our developmental and clinical accomplishments. Most notably, we applied our proprietary cell manufacturing technolo...

4 months ago - TheFly

Lineage Cell Therapeutics Earnings Call Transcript: Q1 2026

Expanded cell therapy pipeline with new programs in ophthalmology and diabetes, robust manufacturing advances, and strong cash position. OpRegen continues to show promise as a disease-modifying treatment, with multiple clinical and partnership milestones anticipated in 2026.

4 months ago - Transcripts